Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

Amit Bar-Or, Peter A.J. Calabresi, Douglas Arnlod, Clyde Markowitz, Stuart Shafer, Lloyd H. Kasper, Emmanuelle Waubant, Suzanne Gazda, Robert J. Fox, Michael Panzara, Neena Sarkar, Sunil Agarwal, Craig H. Smith

Research output: Contribution to journal › Article › peer-review

353 Scopus citations

Fingerprint

Dive into the research topics of 'Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial'. Together they form a unique fingerprint.

Medicine & Life Sciences